Validation

Gene Symbol Curated Descriptions Cell Lines Isolations Validations Control-case Tumor Stage & Subtype Clinical Use PMID
S1PR2 S1P2 is released from breast cancer cells in exosomes and is processed by fibroblasts to promote ERK signaling and proliferation of breast cancer cells MDA-MB-231 ultracentrifugation electron microscopy 30034630
hsa-miR-130a Comparing the miRNAs in MDA-Exo to MCF-Exo showed a higher expression of tumorigenic mir-130a in MDA-Exo. it has been shown that mir-130a contribute to tumorigenesis of colon cancer by regulating TGB-β/Smad signaling MCF7,MDA-MB231 ultracentrifugation electron microscopy 24468161
hsa-miR-1246 Hsa-miR-1246 promotes cell proliferation,invasion and drug resistance by targeting CCNG2 in breast cancer MDA-MB-231 ultracentrifugation scanning electron and confocal microscopy metastasis 29216623
hsa-miR-93-5p Of 384 miRNAs, three miRNAs (miR-338-3p, miR-340-5p, and miR-124-3p) were significantly upregulated and eight (miR-29b-3p, miR-20b-5p, miR-17-5p, miR-130a-3p, miR-18a-5p, miR-195-5p, miR-486-5p, and miR-93-5p) were significantly downregulated in the patients with recurrence ExoQuick nanosight LM10 instrumen western blottingt 16 breast cancer plasma samples (case) 16 healthy plasma samples (control) Luminal (ER and/or PR + and HER2 -),HER2 (ER and/or PR +/- and HER2 +),TN (ER and PR and HER2 -) recurrence 29050253
hsa-miR-124-3p Of 384 miRNAs, three miRNAs (miR-338-3p, miR-340-5p, and miR-124-3p) were significantly upregulated and eight (miR-29b-3p, miR-20b-5p, miR-17-5p, miR-130a-3p, miR-18a-5p, miR-195-5p, miR-486-5p, and miR-93-5p) were significantly downregulated in the patients with recurrence ExoQuick nanosight LM10 instrumen western blottingt 16 breast cancer patients with recurrence (case) 16 breast cancer patients without recurrence (control) Luminal (ER and/or PR + and HER2 -),HER2 (ER and/or PR +/- and HER2 +),TN (ER and PR and HER2 -) recurrence 29050253
TRPC5 CirExo-TRPC5 might act as a noninvasive chemoresistance marker and might serve as an adjuvant to the current imaging examination-based chemoresistance ultracentrifugation Immunofluorescence confocal laser scanning microscope 131 breast cancer female patients (case) Anthracycline/taxane-based chemotherapy 28032400
hsa-miR-1246 Based on the selective enrichment and absolute abundance, we identified miR-1246, miR-122, miR-21, and let-7a as candidate exosome microRNAs that may serve as biomarkers indicative of breast cancer ultracentrifugation, Exoquick-TC reagent (System Biosciences,Mountain View,CA,USA) electron microscopy,nanoparticle tracking analysis,and western blot 16 breast cancer plasma samples (case) 16 healthy plasma samples (control) ER+/-,PR+/-,HER2+/- stages II, III breast cancer 27608715
hsa-miR-21 Based on the selective enrichment and absolute abundance, we identified miR-1246, miR-122, miR-21, and let-7a as candidate exosome microRNAs that may serve as biomarkers indicative of breast cancer centrifugation ultracentrifugation and filtration or with the Exoquick-TC reagent (System Biosciences,Mountain View,CA,USA) electron microscopy,nanoparticle tracking analysis,and western blot 16 breast cancer plasma samples (case) 16 healthy plasma samples (control) ER+/-,PR+/-,HER2+/- stages II, III breast cancer 27608715
hsa-miR-223-3p Exosomal miR-223-3p may be a useful preoperative biomarker to identify the invasive lesions of DCIS patients diagnosed by biopsy MCF7 ultracentrifugation electron microscope 175 breast cancer patients (case) 3 healthy controls (control) ductal carcinoma in?situ (DCIS) breast cancer? early diagnosis 29805680
HER2 The exosomal HER2 expression levels were almost consistent with that in tumor tissues assessed by immunohistochemical staining MCF7,MDA-MB-231 centrifugation transmission electron microscopy 19 breast cancer patients (case) early diagnosis 28369094

Pages